In recent years, the systemic treatment of metastatic NSCLC has been revolutionized by the development of both targeted therapies such as EGFR inhibitors as well as immunotherapy, which have significantly improved survival outcomes. Here, EGFR is linked to non-small cell lung carcinoma.